Evaxion Biotech A/S — Form 6-K Summary
Business context and reporting period
Evaxion Biotech A/S, a Danish biotechnology company, filed Form 6-K for August 2023 on August 11, 2023. The filing reports a capital-markets transaction under the company’s at-the-market (ATM) offering program.
Key financial and capital metrics
- ADSs sold: 11,348 American Depositary Shares, with each ADS representing one ordinary share.
- Pricing: Volume-weighted average price of $1.2821 per ADS.
- Net proceeds: Approximately $14,020 after fees and expenses.
- Share capital: Nominal share capital increased by DKK 11,348 to DKK 27,651,648.
- Revenue, profit, cash flow, margins, debt and liquidity: The filing does not provide operating or balance-sheet financial results or a clear liquidity figure.
Material changes versus the prior comparable period
The filing does not present comparative financial statements or period-over-period operating results. The reported change is the issuance of 11,348 ordinary shares through the ATM program, effective July 18, 2023, which increased outstanding share capital and resulted in approximately $14,020 of net proceeds.
Guidance, outlook, risks and unusual items
- The filing provides no earnings guidance, operating outlook or management discussion of risks.
- The ATM sales were conducted under the Capital Demand Sales Agreement with Jones Trading Institutional Services LLC dated October 3, 2022.
- The company’s Articles of Association were amended to reflect the share issuances.
- The report is incorporated by reference into specified Form S-8, Form F-3 and Form F-1 registration statements, to the extent not superseded by later filings.
Investor verification points
- Verify the number of ADSs issued, the $1.2821 average sale price and the approximately $14,020 net proceeds.
- Assess the effect of the issuance on total shares outstanding and potential dilution.
- Review the amended Articles of Association attached as Exhibit 1.1.
- Consult subsequent filings for the company’s cash balance, funding needs, operating performance and any additional ATM activity.